Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage biopharmaceutical company focused on developing and commercializing next-generation immuno-oncology therapies for people living with cancer. The company's approved product LOQTORZI (toripalimab-tpzi) is a next-generation PD-1 inhibitor, and its pipeline includes multiple clinical-stage immuno-oncology candidates — Tagmokitug (CCR8), Casdozokitug (IL-27) — targeting the tumor microenvironment to potentially extend patient survival across tumor types. Founded by Denny Lanfear, who took Coherus public in 2014, the company has over a decade of execution history across multiple disease areas. Its leadership team brings deep expertise in immunology, oncology, manufacturing, supply chain, and commercial drug development.